August 16,
2002
CCLE Files Comments with
the DEA
Concerning the Agency's Intention to Schedule 2C-T-7
The Center for Cognitive Liberty & Ethics
(CCLE) attorney Richard Glen Boire has submitted written comments to the DEA
opposing the agency’s intent to schedule the compound 2C-T-7. This
compound, (full name 2,5-dimethoxy-4-(n)-propylthiophene- thylamine) was
first synthesized by Dr. Alexander Shulgin in 1981. In July, the DEA filed
a Notice of Intent to place 2C-T-7 on Schedule I
of the Controlled Substances Act, contending that 2C-T-7 is a dangerous drug
of abuse with no medical value.
In the comments submitted to the DEA, the CCLE
opposed the scheduling of 2C-T-7 as an infringement on cognitive liberty –
the fundamental right of the individual to self-determine his or her mental
processes and to engage in multiple modes of thought. Further, the agency relied on Internet postings discussing the
compound as evidence of “widespread” abuse, equating discussion of
using this unscheduled substance with its misuse. The CCLE
maintains that this is flawed logic, chills the First Amendment rights of
those discussing 2C-T-7 (or any subject) via the Internet, and discourages
the dissemination of important health and safety information about
drugs.
“Placing 2C-T-7 in Schedule I of
the Controlled Substances Act will make criminals out of otherwise
law-abiding citizens who merely possess the substance, and/or ingest it
responsibly to occasion a particular mode of thinking, " writes Mr.
Boire. "Freedom of thought is inextricably linked with the freedom
and autonomy of each citizen to self-determine his or her own brain
chemistry. By placing 2C-T-7 into Schedule I of the Controlled Substances
Act, the fundamental cognitive liberty of peaceful, responsible, and
intelligent Americans to modulate their own thinking processes is
infringed upon in an overly broad and unconstitutional manner."
The CCLE is involved in this and many other projects
that impact intellectual autonomy and freedom of thought. For more
information on supporting our work, please visit www.cognitiveliberty.org
Read the CCLE's
complete comments to the DEA in the matter of 2C-T-7. (pdf)
Resources:
Addendum Sept. 2002: 2C-T-7 Scheduled.
Entheogens and Drug Policy Project
Ask
Dr. Shulgin
Receive Top News
Alerts in your E-mail box! >> Learn
more |
